Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.52 |
| ▸ | NR1I2 | O75469 | 9/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | ITGA1 | P56199 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CYP24A1 | Q07973 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6015138 | 0.93 | HPGD (0.54) | LMNASMN1; SMN2HTTHIF1AHPGD | |
| SCHEMBL5300317 | 0.91 | NR1I2 (0.48) | LMNASMN1; SMN2HTTHIF1AHPGD | |
| SCHEMBL5300596 | 0.91 | HPGD (0.50) | LMNASMN1; SMN2HTTHIF1AHPGD | |
| SCHEMBL5292819 | 0.91 | NR1I2 (0.48) | LMNASMN1; SMN2HTTHPGDALDH1A1 | |
| SCHEMBL5300268 | 0.88 | NR1I2 (0.61) | LMNAHTTHPGDALDH1A1MAPT | |
| SCHEMBL5410518 | 0.88 | NR1I2 (0.61) | LMNASMN1; SMN2HTTHIF1AHPGD | |
| SCHEMBL5291553 | 0.88 | NR1I2 (0.60) | LMNASMN1; SMN2HTTHPGDALDH1A1 | |
| SCHEMBL2292224 | 0.88 | NR1I2 (0.56) | LMNAHTTHPGDALDH1A1MAPT | |
| SCHEMBL2299260 | 0.85 | HPGD (0.48) | LMNAHTTHPGDALDH1A1MAPT | |
| SCHEMBL5290026 | 0.85 | AKR1C3 (0.49) | HPGDALDH1A1MAPTNR1I2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1828144-A2 | INTEGRIN ANTAGONISTS USEFUL AS ANTICANCER AGENTS | OSI Pharmaceuticals, Inc. (US) | 2007-09-05 | — | — | EP | claimed |
| US-20060116383-A1 | Integrin antagonists useful as anticancer agents | ALCATEL LUCENT (FR) | 2006-06-01 | — | — | US | claimed |
| WO-2006053342-A2 | INTEGRIN ANTAGONISTS USEFUL AS ANTICANCER AGENTS | OSI PHARMACEUTICALS, INC. (US) | 2006-05-18 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116383-A1 | Integrin antagonists useful as anticancer agents | ITGB5, ITGA5, ITGB1 | LMNA 1740/4885SMN1; SMN2 2159/4885HTT 4869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.